FDA denies OTC monitoring request
This article was originally published in The Tan Sheet
Executive SummaryA request by the Synthetic Organic Chemical Manufacturers Association for FDA to implement a program for monitoring the impurity profiles of imported OTC drugs is denied. The agency's Oct. 13 1response to SOCMA's 2006 citizen 2petition says FDA's existing sampling and testing program for drug products and its good manufacturing practice inspection and surveillance efforts are "more comprehensive and appropriate" than SOCMA's recommendations (3"The Tan Sheet" Nov. 5, 2007). FDA denied most of SOCMA's other provisions, including requests to identify foreign facilities as a significant risk factor in inspections and risk-ranking foreign and domestic drug firms together. However, the agency did accede to the association's request for a publicly available database of foreign and domestic drug manufacturers, mainly because FDA is already developing such a system
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.